Generation Bio

General Information
Business:

 

We are an innovative genetic medicines company creating a new class of gene therapy utilizing our proprietary non-viral gene therapy platform to provide durable, redosable treatments for millions of patients living with rare and prevalent diseases. Our non-viral gene therapy platform incorporates our high-capacity DNA construct called closed-ended DNA, or ceDNA; our cell-targeted lipid nanoparticle delivery system, or ctLNP; and our established, scalable capsid-free manufacturing process. Using our approach, we are developing novel gene therapies to provide targeted delivery of genetic payloads that include large and multiple genes to a range of tissues across a broad array of diseases. We are also engineering our gene therapies to be redosable, which may enable individualized patient titration to reach the desired level of therapeutic expression and to maintain efficacy throughout a patient’s life.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 85
Founded: 2016
Contact Information
Address 301 Binney Street, Cambridge, MA 02142, US
Phone Number (617) 655-7500
Web Address http://www.generationbio.com
View Prospectus: Generation Bio
Financial Information
Market Cap $848mil
Revenues $0 mil (last 12 months)
Net Income $-64.9 mil (last 12 months)
IPO Profile
Symbol GBIO
Exchange NASDAQ
Shares (millions): 10.5
Price range $19.00 - $19.00
Est. $ Volume $200.0 mil
Manager / Joint Managers J.P. Morgan/ Jefferies/ Cowen
CO-Managers Wedbush PacGrow
Expected To Trade: 6/12/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change